199 related articles for article (PubMed ID: 27486136)
21. New insights in efficacy of different enzyme replacement therapy dosages in Fabry disease: Switch studies data following agalsidase beta shortage.
Riccio E; Pisani A
Clin Genet; 2023 Mar; 103(3):371-376. PubMed ID: 36373246
[TBL] [Abstract][Full Text] [Related]
22. Agalsidase alfa: specific treatment for Fabry disease.
Mehta A
Hosp Med; 2002 Jun; 63(6):347-50. PubMed ID: 12096664
[TBL] [Abstract][Full Text] [Related]
23. [Enzyme replacement therapy in Fabry's disease].
Alvarez L; del Pozo C; Trigueros M; Sánchez L; Albero MD; López-Menchero R; Ortega E
Nefrologia; 2005; 25(3):322-7. PubMed ID: 16053014
[TBL] [Abstract][Full Text] [Related]
24. Do we need more intensive enzyme replacement therapy for Anderson-Fabry disease?
Basic-Jukic N; Kes P; Mokos I; Coric M
Med Hypotheses; 2009 Apr; 72(4):476-7. PubMed ID: 19124204
[No Abstract] [Full Text] [Related]
25. Long-term changes in arterial structure and function and left ventricular geometry after enzyme replacement therapy in patients affected with Fabry disease.
Collin C; Briet M; Tran TC; Beaussier H; Benistan K; Bensalah M; Mousseaux E; Froissart M; Bozec E; Laurent S; Boutouyrie P; Germain DP
Eur J Prev Cardiol; 2012 Feb; 19(1):43-54. PubMed ID: 21450622
[TBL] [Abstract][Full Text] [Related]
26. Enzyme replacement therapy for Fabry's disease.
Waldek S; Germain DP; Wanner C; Warnock DG
Lancet; 2010 May; 375(9725):1523; author reply 1523-4. PubMed ID: 20435225
[No Abstract] [Full Text] [Related]
27. Response to commentary: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study - determination of immunogenicity.
Warnock DG; Wallace EL
J Med Genet; 2024 May; 61(6):534-535. PubMed ID: 38589225
[No Abstract] [Full Text] [Related]
28. Comment to: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study-determination of immunogenicity.
Lenders M; Brand E
J Med Genet; 2024 May; 61(6):531-533. PubMed ID: 38538083
[No Abstract] [Full Text] [Related]
29. Enzyme replacement therapy for Fabry's disease.
Deegan P
Lancet; 2010 May; 375(9725):1522-3; author reply 1523-4. PubMed ID: 20435224
[No Abstract] [Full Text] [Related]
30. Long-Term Effects of Enzyme Replacement Therapy for Anderson-Fabry Disease.
Tsujiuchi M; Ebato M; Maezawa H; Mizukami T; Nogi A; Ikeda N; Iso Y; Suzuki H
Int Heart J; 2019 Jan; 60(1):208-214. PubMed ID: 30464119
[TBL] [Abstract][Full Text] [Related]
31. Schiffmann R, Rapkiewicz A, Abu-Asab M, Ries M, Askari H, Tsokos M, Quezado M. Pathological findings in a patient with Fabry disease, who died after 2.5 years of enzyme replacement. Virchows Arch. 2005 Nov 29; 1-7.
Politei J
Virchows Arch; 2006 Jun; 448(6):873. PubMed ID: 16523259
[No Abstract] [Full Text] [Related]
32. Enzyme replacement therapy and Fabry kidney disease: quo vadis?
Warnock DG
J Am Soc Nephrol; 2007 May; 18(5):1368-70. PubMed ID: 17429046
[No Abstract] [Full Text] [Related]
33. Kidney transplantation from a mother with unrecognized Fabry disease to her son with low α-galactosidase A activity: A 14-year follow-up without enzyme replacement therapy.
Odani K; Okumi M; Honda K; Ishida H; Tanabe K
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():57-9. PubMed ID: 26971403
[TBL] [Abstract][Full Text] [Related]
34. [Fabry disease: new clinical research--current therapeutic perspectives].
Beck M
Wien Klin Wochenschr; 2003 Apr; 115(7-8):215-7. PubMed ID: 12778772
[No Abstract] [Full Text] [Related]
35. Reduction in ECG abnormalities and improvement of regional left ventricular function in a patient with Fabry's disease during enzyme-replacement therapy.
Prinz C; Farr M; Hering D; Horstkotte D; Faber L
Clin Res Cardiol; 2010 Jan; 99(1):53-5. PubMed ID: 19774328
[No Abstract] [Full Text] [Related]
36. Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement Therapy.
Nakano S; Tsukimura T; Togawa T; Ohashi T; Kobayashi M; Takayama K; Kobayashi Y; Abiko H; Satou M; Nakahata T; Warnock DG; Sakuraba H; Shibasaki F
PLoS One; 2015; 10(6):e0128351. PubMed ID: 26083343
[TBL] [Abstract][Full Text] [Related]
37. Enzyme replacement in the treatment of Fabry's disease. Is there a point-of-no-return?
del Toro N; Milán JA; Palma A
Nephrol Dial Transplant; 2004 Apr; 19(4):1018. PubMed ID: 15031378
[No Abstract] [Full Text] [Related]
38. Anderson-Fabry disease: enzyme replacement therapy.
Leon-Mateos A; Fernández-Redondo V; Beiras A; Toribio J
Acta Derm Venereol; 2004; 84(1):88-9. PubMed ID: 15040494
[No Abstract] [Full Text] [Related]
39. [Enzyme therapy in Fabry disease: when scarcity of one enzyme illustrates the vulnerability of biotech].
Lidove O; Choukroun G; Bekri S; Viot G; Tsimaratos M; Joly D
Presse Med; 2010 May; 39(5):527-9. PubMed ID: 20194001
[No Abstract] [Full Text] [Related]
40. Successful long-term enzyme replacement therapy in a young adult with Fabry disease.
Kampmann C; Kalkum G; Beck M; Whybra C
Clin Genet; 2013 Apr; 83(4):395-6. PubMed ID: 22881192
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
